Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

All news

Show

From To
It takes 4 hands to open this ‘consent condom,’ but does that really equal consent?

Argentinian sex toy retailer Tulipán has released a limited-edition condom in a special “tamper proof” package that requires four hands to open. Their goal is to raise awareness about consent. “Why can this box only be opened by two [people]? Because this is how consent works in relationships. Everything has to be two,” reads the tagline on Tulipán’s ad for the condom on Twitter.

Published
15 April 2019
From
LGBTQ Nation
HIV Stigma Makes Zambian Mothers Think Twice About Exclusive Breastfeeding

In Zambia, women who are HIV-positive are encouraged to exclusively breastfeed their babies, but those mothers say extended breastfeeding is a telltale sign that they have the virus.

Published
15 April 2019
From
Global Press Journal
London councils agree to take 60% new PrEP trial patients, but it might not be enough

A stalemate over who would take more patients on to PrEP trial has ended. London councils have agreed to increase places on city PrEP trial.

Published
15 April 2019
From
Gay Star News
Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment?

When HIV drugmaker ViiV announced in late 2017 that it had received Food and Drug Administration (FDA) approval for Juluca (dolutegravir/rilpivirine), the first effective two-drug, single-pill HIV regimen in the modern treatment era, community activists hoped that its price would reflect the fact that it contained one drug fewer than three-drug tablets like Complera (rilpivirine/tenofovir disoproxil fumarate/FTC), Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide), Stribild (cobicistat/elvitegravir/FTC/tenofovir disoproxil fumarate), and Triumeq (abacavir/dolutegravir/lamivudine), all of which are generally priced between $2,600 and $3,500 a month in the U.S.

Published
15 April 2019
From
The Body
Jose Arribas, MD, on the Challenges That Come With Long-Acting Injectables

The announcement of the results of the FLAIR and ATLAS studies at the Annual Conference on Retroviruses and Opportunistic Infections in March was a major step forward in the field of long-acting injectables for the treatment and management of HIV. But with advances come challenges.

Published
15 April 2019
From
Contagion Live
More Londoners to receive HIV prevention medicine

In a boost to HIV prevention in the capital, London boroughs have agreed to provide over 4,000 extra places on the PrEP Impact Trial. The trial – a national programme led by NHS England in partnership with Public Health England and local authorities – supplies PrEP (an HIV prevention medicine) free of charge to individuals considered to be at high risk of exposure to HIV. The expansion, which will take place over the coming weeks, represents a 60% increase in the trial places available to Londoners. London already accounts for 7,609 trial places – a higher figure than the rest of England combined.

Published
12 April 2019
From
London Councils
Health expert says hepatitis C could be eliminated quickly in Scotland

A leading expert in hepatitis C has said it could be removed from Scotland in the next five years if efforts to cure people were "energised".

Published
12 April 2019
From
BBC News
South Africa: Health department scrambles to stop US cut in HIV funds

In a surprise move barely six weeks after announcing that SA was to get an extra $1.2bn to support its HIV/AIDS programmes over the next two years, US global AIDS coordinator Deborah Birx said Pepfar’s programmes are performing so poorly in SA that funding should be cut from the start of the next US financial year, which begins on October 1.

Published
12 April 2019
From
Business Day
Gilead Lawsuits: 41 HIV and PrEP Patients File California Personal Injury Case Over Gilead's TDF-Based Drugs

41 patients from 12 states nationwide who are living with HIV or AIDS or were on PrEP filed a personal injury lawsuit against Gilead Sciences Inc. seeking to hold the Bay Area drug maker accountable for actions around its failure to rectify a known defect in the drug formulation of one of its most widely prescribed medications: tenofovir disoproxil fumarate (TDF) knowing that a safer alternate, tenofovir alafenamide (TAF) existed in its own laboratory; its failure to warn patients of the damaging side effects of TDF; and the company’s active misrepresentation of TDF’s efficacy and substantial risks.

Published
12 April 2019
From
Associated Press
London: Tower Hamlets Mayor calls for Government to fund PrEP for all to stop HIV transmission

John Biggs, Mayor of Tower Hamlets has written to Matt Hancock the Secretary of State for health, to call for the funding of HIV treatment that could stop the spread of HIV, saving the NHS millions of pounds.

Published
11 April 2019
From
Tower Hamlets council

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.